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1571 ABSTRACT 
Serum albumin crystal forms have been produced which 
exhibit superior x-ray diffraction quality. The crystals are 
produced from both recombinant and wild-type human 
serum albumin, canine, and baboon serum albumin and 
allow the performance of drug-binding studies as well as 
genetic engineering studies. The crystals are grown from 
solutions of polyethylene glycol or ammonium sulphate 
within prescribed limits during growth times from one to 
several weeks and include the following space groups: P2,, 
c2 ,  P1. 
24 Claims, 4 Drawing Sheets 
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ecules such as HSA-CD4 and HSA-Cu,Zn-superoxide dis- 
mutase have been utilized to increase the half-life and 
distribution, and reduce the immunogenicity of these poten- 
tial protein therapeutics. 
In order to study the use of albumin in rational drug 
design, it is necessary to understand its structure and the 
chemistry of drugkgand binding. The power of rational 
drug design has recently been reviewed by Bugg et al., 
Drugs by Design, 92 Scientific American (December, 1993). 
A requirement of rational drug design is the production of 
crystals of the desired target protein which provide for the 
determination of the detailed atomic structure of both the 
parent protein and its complex with the pharmaceutical. A 
tetragonal crystal form of human serum albumin, described 
in U.S. Pat. No. 4,833,233, provided means for the first 
atomic structure determination of human serum albumin. 
Consequently, this crystal form has been utilized to explain 
a great deal about serum albumin structure and chemistry 
particularly in regard to the mode of ligand binding taught 
by Carter & Ho, Structure of Serum Albumin, 45 Advances 
in Protein Chemistry 153 (1994). However, this crystal form 
has the disadvantage of an intrinsic limit on the diffraction 
data, namely to 2.9 angstroms and limited stability under 
x-irradiation. 
SUMMARY OF THE INVENTION 
Thus, it is a purpose of the present invention to overcome 
the disadvantage of the prior art and thereby provide high 
quality crystals of serum albumin. 
In accordance with a preferred embodiment of the inven- 
tion human serum albumin crystals are prepared which 
exhibit x-ray diffraction resolutions to d-spacings of 2.4 
angstroms (A) or less. In a preferred form, the crystals have 
a monoclinic space group P2,, and the following unit cell 
constants a=58.9 (7), b=88.3 (7), ~ 6 0 . 7  (7) and Beta=lOl 
(2) degrees. The crystals are prepared from recombinant or 
naturally isolated serum albumin. 
In another preferred embodiment, canine albumin crystals 
(“CSA”) are prepared which exhibit x-ray diffraction reso- 
lutions to d-spacings of 2.2 angstroms or less. 
It is, therefore, an object of the present invention to 
provide serum albumin crystals for studies directed toward 
improving the efficacy, delivery or metabolism of various 
high potential pharmaceuticals that are rendered ineffective 
by serum albumin. 
This and other objects of the present invention will 
become apparent from the detailed description to follow. 
BRIEF DESCRIPTION OF THE DRAWINGS 
There follows a detailed description of the preferred 
embodiments of the present invention which are to be taken 
together with the accompanying drawings, wherein: 
FIG. 1 is a photograph showing one of the crystal forms 
(Form I) of HSA embodying the present invention. 
FIG. 2 is a photograph showing another one of the crystal 
forms (Form II) of HSA embodying the present invention. 
FIG. 3 is a photograph showing high quality crystals of 
CSA, space group P1. 
FIG. 4 is a photograph showing high quality crystals of 
HSA containing from 3 to 10 molar excess of long chain 
fatty acid, monoclinic space group C2 (Form ILI). 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
Monoclinic plate-like crystals of human serum albumin in 
accordance with the method of the present invention are 
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ORIGIN OF THE INVENTION 5 
This invention was made by an employee of the United 
States Government and may be manufactured and used by or 
for the Government for governmental puposes without the 
payment of any royalties. 10 
FIELD OF THE INVENTION 
The present invention is related to the use of albumin in 
structural studies related to drug binding and genetic engi- 
neering and, more particularly, to high quality crystal forms 
prepared from human, baboon and canine serum albumin 
which are suitable for conducting drug and ligand binding 
experiments. 
BACKGROUND OF THE INVENTION 
Serum albumin, a protein of multiple functions and mani- 
fold applications, is one of the most extensively studied 
proteins in biochemistry. As the most abundant protein in the 
circulatory system and with typical blood concentrations of 
5 g/100 ml, serum albumin contributes 80% to colloid 
osmotic blood pressure. In addition, it has now been deter- 
mined that albumin is chiefly responsible for the mainte- 
nance of blood pH. It is located in every tissue and bodily 
secretion, with the extracellular protein comprising 60% of 
total albumin. In mammals, albumin is synthesized by the 
liver and possesses a half-life in circulation of 19 days. 
Complete amino acid sequences are known for bovine, rat, 
and human serum albumins. 
While the principal function of serum albumin remains 
unknown, it is clear that serum albumin contributes to many 
transport and regulatory processes. Many studies have 
focused on the multi-functional binding properties of serum 
albumin to various metals, fatty acids, hormones, and a wide 
spectrum of therapeutic drugs. The majority of these binding 
studies have involved human serum albumin (“HSA”) and 
many have shown that the distribution, free concentration, 
and metabolism of various pharmaceuticals can be signifi- 
cantly altered as a function of the magnitude of binding to 
HSA. 
Serum albumin is the principal carrier of fatty acids that 
are otherwise insoluble in circulating plasma. But albumin 
performs many other functions as well, such as sequestering 
oxygen free radicals and inactivating various toxic lipophilic 
metabolites such as bilirubin. Although albumin has a broad 
affinity for small, negatively charged aromatic compounds, 
it has high affinities for fatty acids, hematin, and bilirubin. 
Additionally, it forms covalent adducts with pyridoxal phos- 
phate cysteine, glutathione, and various metals, such as 
It is widely accepted in the pharmaceutical industry that 
the overall distribution, metabolism, and efficacy of many 
drugs can be altered based on their affinity to serum albumin. 
In addition, many promising new drugs are rendered inef- 
fective because of their unusually high affinity to serum 
albumin. Some studies have suggested that modified serum 
albumin may be used as a selective contrast agent for tumor 
detection andor therapy. Other studies have demonstrated 
that albumin may be used to deliver toxic compounds for 
elimination of Mycobacterium tuberculosis via receptor- 
mediated drug delivery. Recently, chimeric albumin mol- 
Cu(n), NiCn) Hgm), AgOI), and AuO). 
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grown from a precipitant solution of polyethylene glycol 
(“PEG”), and a buffer, with concentration of reagents and 
pH being carefully controlled within prescribed limits. Any 
of the three basic techniques generally used for growth of 
protein crystals, that is, “hanging-drop” or vapor diffusion, 
dialysis and batch methods may be employed. The hanging- 
drop method is, however, preferred. 
Further, either recombinant HSA or naturally isolated 
HSA may be used for crystal growth. 
In the hanging drop method a small drop of protein 
solution is placed on a cover slip, or glass plate, which is 
inverted over a well of solution and sealed. The solution in 
the well contains a precipitating agent, which is also present 
in a lesser amount in the protein droplet. The function of the 
precipitating agent is twofold. First, the solution in the well 
is initially at a lower vapor pressure than the protein droplet 
so that evaporation progresses at a rate fixed by the differ- 
ence in the vapor pressures and the distance by which the 
vapor, usually water, must diffuse. Second, the precipitating 
agent lowers the solubility of the protein in solution by 
competing with the protein for available solvent. Thus, as 
evaporation from the protein droplet occurs, the solution 
becomes supersaturated in protein. Under the appropriate 
conditions including pH, protein concentration and tempera- 
ture, crystallization of the protein or macromolecule then 
A stock solution of PEG is prepared by combining 50 
weight percent PEG having a molecular weight on the order 
of 3350 gramdmole with 50 weight percent water. The 
precipitant solution is then prepared by mixing the stock 
solution with an appropriate buffer (usually 0.05 molar) to 
adjust the pH and starting concentration. Appropriate buffers 
include sodium acetate, sodium citrate and Tris (hydroxym- 
ethyl) aminomethanemaleate and potassium phosphate. 
However, monobasic sodium phosphate (NaHPO,) is the 
preferred buffer. As a general guideline for preparing the 
precipitant solution, 35 weight percent of the stock solution 
is combined with 65% of the phosphate buffer which has a 
pH between 4.6 and 8.0. Most preferably, the buffer solution 
remains neutral, that is, pH 7.5. 
Once the precipitant solution is prepared, additional pH 
adjustments may be required to compensate for variations in 
pH which can arise from variations in molecular weight and 
residue content of PEG. These adjustments are carried out 
by adding small amounts of a base such as potassium 
hydroxide or an acid such as hydrochloric acid to the 
precipitant solution. If the hanging-drop method is 
employed for crystal growth, the droplet is preferably 
formed using 10 microliters (pl) of the precipitant solution 
and 10 pl of HSA having a concentration of 90 to 200 mg/ml, 
preferably 120 mg/ml. The droplet is sealed in a chamber 
and equilibrated over a 1 ml reservoir solution of the 
precipitant solution. Within ten days to three weeks, crystals 
appear and reach sizes of up to 0.7 rnm in the largest 
dimension, with total dimensions being on the order of 0.7 
mmx0.15 mmx0.2 mm. 
HSA crystals appear in two forms. FIG. 1 is a photograph 
showing the Form I crystals which typically appear before 
the more preferred, Form II crystals. The Form I crystals are 
less mechanically stable and exhibit poorer diffraction char- 
acteristics. FIG. 2 is a photograph showing the Form II 
crystals which grow in the monoclinic space group P2, and 
possesses the following unit cell constants: a=58.9 (7), 
b88 .3  (7), ~ 6 0 . 7  (7), Beta=lOl (2) degrees. 
The quality of protein crystals is determined by the ability 
of the crystal to scatter x-rays of wavelengths (typically 1.0 
occurs. 
4 
to 1.6 A) suitable to determine the atomic coordinates of the 
protein. The measure of the quality is determined as a 
function of the highest angle of scatter (the ultimate or 
intrinsic resolution) and according to Bragg’s Law: n k 2 d  
sine, d may be determined, and represents the resolution of 
the crystal form in angstroms. Thus, this measurement is 
routinely used to judge the ultimate usefulness of protein 
crystals. The International Union of Crystallographers has 
determined that there are 230 unique ways in which chemi- 
1o cal substances, proteins or otherwise, may assemble in 
three-dimensions to form crystals. These are called the 230 
“space groups.” The designation of the space group in 
addition to the unit cell constants (which define the explicit 
size and shape of the cell which repeats within the crystal) 
15 is routinely used to uniquely identify a crystalline substance. 
Certain conventions have been established to ensure the 
proper identification of crystalline materials and these con- 
ventions have been set forth and documented in the Inter- 
national Tables for Crystallography, incorporated herein by 
High quality crystals of baboon serum albumin (“BbSA”) 
are prepared under identical conditions to those for human 
serum albumin. The crystals grow in the monoclinic space 
group P2, possess substantially the same unit cell constants 
25 as the HSA crystals. The BbSA forms can be used as 
substitutes in studies of human druglalbumin interactions 
where crystallization of the complexes are only possible 
with this species. The principles of this application has been 
convincingly demonstrated at the atomic level by Ho et al., 
30 X-ray and primary structure of horse serum albumin (Equus 
caballus) at 0.27-nm resolution, 215 Eur. J. Biochem. 205 
(1 993) in the comparison of the ligand binding properties of 
horse serum albumin with human serum albumin, and by 
Carter and Ho, supra. Thus, the precise atomic interactions 
35 between protein and ligand can only be provided by a 
determination of the corresponding crystal structure. 
Although most of the important key residues involved in 
ligand binding by albumin are conserved among the various 
species, there can also exist selective differences in albumin 
40 ligand binding chemistry between species as discussed in C. 
F. Chignell, 2 CRC Handbook of Biochemistry and Molecu- 
lar Biology, 554-582 (1976). 
FIG. 3 is a photograph showing high quality crystals of 
CSA. The crystals possess the following unit cell constants: 
45 a=51.7 (7) A, b66 .6  (7) A, c=108.1 (9) A, alpha=90.4 (9), 
beta=107.9 (9), gamma43.1 (9) degrees. These crystals 
were grown using a hanging-drop method with 5 6 6 0 %  
volume/volume (v/v) saturated ammonium sulphate solu- 
tion. Appropriate buffers for preparing CSA crystals include 
50 TIUS, cacodylate, citrate phosphate and potassium phos- 
phate. However, the preferred buffer is KHPO, at pH 7.5 to 
8.0. The droplet was prepared using 10 pl of the precipitant 
solution and 10 pl of CSA having a concentration of 180 
mg/ml, although CSA crystals may be grown with lower 
55 protein concentration. The resulting crystals exhibited x-ray 
diffraction resolutions to d-spacings less than 2.2 angstroms, 
thereby providing a means for high resolution studies of 
drugnigand interaction with albumin. Both baboon and 
canine serum albumin are important in drug efficacy, and 
60 delivery, i.e., rational drug design, because they represent 
important animal models for human efficacy trials. In par- 
ticular, differences in the chemistry of drug binding between 
albumins often reflects important differences in their respec- 
tive albumins, as taught by Carter & Ho, supra. This 
65 difference is reflected in their primary structures. Thus, an 
understanding of these interactions may provide further 
insight in future studies of new promising pharmaceuticals 
2o reference. 
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in human trials. Similarly their different chemistries also 
provide other avenues in genetic engineering studies and the 
production of novel albumin based therapeutics. 
T~ obtain structural idormation about the protein/dmg 
the second commonly practiced method, the drugs or ligands 
may be soaked into the crystal because of the inherently 
large aqueous solvent channels present in protein crystals. 
(See, e.& Cmeret al., 2 4 4 S c i e w  1195-1198 (1989).)The 
interaction to allow rational drug design, it is also necessary 
to prepare a crystal of the complex, the complex being the 
5 crystal1ine 
described above to provide the 
thus formed follOws the Same procedure 
density Of the drug 
drug bound to the of interest. The difference in the genetic engineering studies 
can be produced using two different methods, is that there is no complex formed. Instead, a crystal of the 
prescribed conditions set forth for the native Serum albu- IO methods, the x-ray data is collected, the resulting structure 
albumin. Crystals of the complex 
a first 
method, the actual complex itself is cryst&zed using the genetically altered albumin is grown by the prescribed 
min(s), i.e., HSA, BbSA or CSA. Once crystals of suitable is refined by any Of a Of known methods, and the 
size have grown, x-ray diffraction data are collected. desirable or undesirable consequences of the engineered 
thousands of diffracted x-rays over a period of one to several structure Of the native molecule. 
days depending on the crystal form and the resolution of the 15 In another Preferred tmbodiment of the invention, long 
data required. According to the method, crystals are born- chain fatty acids are added to the HSA in ratios. The phrase 
barded with x-rays, The crystals diffract the rays, creating a “long chain fatty acids” is used to define any of the common 
geometrically precise splatter of spots on photographic film saturated or unsaturated fatty acids such as palmitic, eicon, 
or electronic detectors. The distribution of atoms within the myristic and lauric acid. Furthermore, addition of propionic 
crystal influences the pattern of spots. Subtraction of the 20 acid and caprylic acid in trace amounts from less than 0.1 to 
data, Fligund-Fnutiver using phases from the atomic model of 2 mole fatty acid/mole HSA may enhance the Production of 
the albumin structure produces the electron density of only favorable Crystal form (Form E>. 
the drug molecule. Visualization of the observed electron FIG. 4 is a photograph showing high quality crystals of 
density superimposed on the atomic coordinates derived HSA containing from 3 to 10 molar excess of long chain 
from the same crystal form provides a determination of key 25 fatty acid. These crystals produce a new crystal form, Form 
protein drug interactions that are necessary for rational drug III, which, like the BbSA and CSA crystals, also exhibits 
design. In the normal practice of the invention, this would be favorable diffraction properties as indicated in the table 
an iterative process involving several cycles of modeling below. As will be apparent by the examination of Table 1, the 
with each of the new drugs synthesized as a result of the serum albumin crystals described herein represent very high 
changes suggested by the crystal structure of the complex. In quality and can be reproducibly grown. 
process usually involves the measurements of many tens of change is assessed by direct with the 
TABLE 1 
CRYSTAL DATA ON THE POLYMORPHS OF SERUM ALBUMIN 
Crystal System: Monoclinic Monoclinic Monoclinic Oahorhombic Orthorhombic Tetragonal Tenagonal 
Space Group: 
Unit Cell 
Dimensions 
p = 105.0 
Solvent 
Content: 
n: 
Rmerge: 
Molecules per 
Asymmetric 
Unit 
Diffraction 
Limits 
Protein: 
(Form In) 
References: 
U: 
(A) 
c2 
a = 187.2 
b = 39.0 
c = 96.9 
35% 
118,130 
21,037 
6.1% 
1 
p = 101.9 
p2, 
a = 58.9 
b = 88.3 
c = 60.7 
33% 
66,492 
23,502 
4.6% 
1 
p = 93.3 
c2 
a = 126.5 
b = 39.2 
c = 135.2 
51% 
p21212, 
a = 155.0 
b = 83.0 
c = 122.0 
52% 
P2,2,2 
a = 137.3 
b = 275.0 
c = 58.02 
59% 
P4,2,2 
or P4,2,2 
a = 84.0 
c = 276.0 
P42,2 
a = 187.0 
b = 81.0 
54% 78% 
1* 2* 33 I* 1 
2.4 2.35 2.5 3.7 3.0 3.8 2.9 
HSA 
this work 
(F~I-III n) 
HSA 
this work 
HSA 
(1) 
HSA 
(1) 
HSA 
(2) 
HSA 
(1) 
HSA 
(334) 
Crystal System: Hexagonal Triclinic Monoclinic 
Space Group: 
Unit Cell 
Dimensions 
(nm) 
P6, 
a = 96.2 
c = 144.0 
a = 90.4 
j3 = 107.9 
y = 93.1 
43% 
PI 
a = 51.7 
b = 66.6 
c = 108.1 
p = 100.4 
p2, 
a = 59.0 
b = 86.9 
c = 60.5 
Solvent 
content: 
n: 
Rmerge: 
Molecules per 
Asymmehic 
U: 
28% 
123,203 
42,780 
10.2% 
2 
33% 
16,355 
8,472 
8.3% 
1 1 
5,5 85,466 
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TABLE 1-continued 
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CRYSTAL DATA ON THE POLYMORPHS OF SERUM ALBUMIN 
unit: 
Difh-action 2.7 2.2 2.1 
Limits: 
(A) 
Protein: ESA CSA BbSA 
References: (1,s) This work This work 
n: total number of reflections measured; 
u: number of unique reflections 
Rmerge: I<I,,> - I,ll/<I,l>; 
*: based on published preliminary estimates. 
1. R. J. McClure and B. M. Craven, 239 J. Mol. Bio. 845-849 (1974). 
2. S .  N. Rao et al. 251 J. Biol. Chem. 3191-3193 (1976). 
3. D. C. Carter, et al., 244 Science 1195-1198 (1989). 
4. D. C. Carter, U.S. Pat. No, 4,833,233. 
5.  J. X. Ho et al., 215 Eur, J. Biochem. 201-212, (1993). 
Other co-crystallization complexes have, also been formed 
with iodinated fatty acid of lauric acid and numerous chemi- 
cally diverse ligands, such as bilirubin, hematin zind warfarin 
with suitable diffraction quality with reflections measured 
less than 2.8 angstrom resolution. 
Although the invention has been described in consider- 
able detail with respect to preferred embodiments thereof, 
variations and modifications will be apparent to those skilled 
in the art without departing from the spirit and scope of the 
invention as set forth in the claims. 
We claim: 
1. A method of growing crystals of serum albumin com- 
providing an aqueous solution of serum albumin having a 
concentration of 10 to 220 milligrams per milliliter; 
providing an aqueous precipitant solution Comprising 
polyethylene glycol having a concentration of 17-30% 
(v/v) and a molecular weight of 2000 to 8000 and a 
corresponding buffer solution; 
mixing a droplet of said aqueous serum albumin solution 
with a droplet of said precipitant solution; 
suspending the resulting mixed droplet over a well of 
precipitant solution in a sealed container, the vapor 
pressure of the solution in said well being lower than 
the vapor pressure in the resulting mixed droplet; and 
allowing the suspended mixed droplet to stand for a 
period of time such that a serum albumin crystal in said 
mixed droplet grows to a predetermined size. 
2. The method according to claim 1 wherein the buffer 
solution comprises a monobasic potassium phosphate solu- 
tion. 
3. The method according to claim 1 wherein the concen- 
tration of said aqueous serum albumin solution is approxi- 
mately 120 milligrams per milliliter. 
4. The method according to claim 1 wherein the polyeth- 
ylene glycol has an average molecular weight of 3350. 
5. The method according to claim 1 wherein said poly- 
ethylene glycol is combined with said corresponding buffer 
solution having a pH of 6.8 to 7.8. 
6. The method according to claim 5 wherein said serum 
albumin comprises human serum albumin. 
7. The method according to claim 6 further comprising the 
step of adding a long chain fatty acid to the precipitant 
solution in molar ratios of 0.1 to 10 per human serum 
albumin molecule. 
8. The method according to claim 5 wherein said serum 
albumin comprises baboon serum albumin. 
9. The method according to claim 8 M e r  comprising the 
step of adding a long chain fatty acid to the precipitant 
prising the steps of: 
solution in molar ratios of 0.1 to 10 per baboon serum 
10. The method according to claim 1 wherein the aqueous 
precipitant solution Comprises saturated ammonium sulfate 
having a concentration of 35-50% (v/v). 
11. The method according to claim 10 wherein the cor- 
25 responding buffer solution has a pH of 1.2 to 8.2. 
12. The method according to claim 11 wherein said serum 
albumin comprises canine serum albumin. 
13. The method according to claim 12 further Comprising 
the step of adding long chain fatty acids to the precipitant 
30 solution in molar ratios of 0.1 to 2 per canine serum albumin 
molecule. 
14. A serum albumin crystal prepared by the method of 
claim 1, wherein the serum albumin is selected from the 
group consisting of human serum albumin, baboon serum 
albumin and canine serum albumin. 
15. A method of growing crystals of serum albumin 
Comprising the steps of: 
providing an aqueous solution of serum albumin having a 
concentration of 10 to 120 milligrams per milliliter; 
providing an aqueous precipitant solution comprising 
polyethylene glycol having a concentration of 17-30% 
(v/v) and a molecular weight of 2000 to 8000 and a 
corresponding buffer; 
combining said serum albumin solution with said precipi- 
tant solution and allowing the combined solution to 
stand for a predetermined time until a serum albumin 
crystal therein grows to a predetermined size. 
16. The method according to claim 15 wherein said serum 
albumin solution is disposed within a semipermeable size 
exclusion membrane and said precipitant solution is com- 
50 bined with the serum albumin solution by diffusion through 
said membrane. 
17. The method according to claim 15 wherein said step 
of combining precipitant solution comprises slowly adding 
the serum albumin solution to the precipitant solution, 
55 sealing the resulting solution in a container and allowing the 
resulting solution to stand. 
18. The method according to claim 15 wherein said 
corresponding buffer solution has a pH of 6.5 to 8.0. 
19. The method according to claim 18 wherein said serum 
albumin comprises human serum albumin. 
20. The method according to claim 18 wherein said serum 
albumin comprises baboon serum albumin. 
21. The method according to claim 18 wherein the aque- 
ous precipitant solution comprises 50-70% (v/v) saturated 
22. The method according to claim 21 wherein said 
2O albumin molecule. 
35 
4o 
45 
65 ammonium sulfate solution. 
corresponding buffer solution has a pH of 7.0 to 8.2. 
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23. The method according to claim 22 wherein said serum 
24. A serum albumin crystal prepared by the method of 
group consisting of human serum albumin, baboon serum 
albumin and canine serum albumin. albumin comprises canine serum albumin. 
claim 15, wherein the serum albumin is selected from the * * * * *  
